**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 78970

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**T-cell immunoglobulin mucin molecule-3, transformation growth factor β, and chemokine-12 and the prognostic status of diffuse large B-cell lymphoma**

Wu H *et al*. Study on the prognosis of DLBCL

Hao Wu, Hui-Cong Sun, Gui-Fang Ouyang

**Hao Wu, Gui-Fang Ouyang,** Department of Hematology, Ningbo First Hospital, Ningbo Clinical Research Center for Hematologic Malignancies, Ningbo 315010, Zhejiang Province, China

**Hui-Cong Sun,** Department of Adult Internal Medicine, Ningbo Women and Children's Hospital, Ningbo 315012, Zhejiang Province, China`

**Author contributions:** Wu H and Ouyang GF for their help in research ideas and design; Ouyang GF for supervision and writing the review; Wu H and Sun HC for their role in research implementation, data collection, and manuscript submission; Wu H for statistical analysis, manuscript editing, and writing.

**Supported by** Ningbo Science and Technology Program, No. 2019A6-10312.

**Corresponding author: Gui-Fang Ouyang, MD, Chief Physician,** Department of Hematology, Ningbo First Hospital, Ningbo Clinical Research Center for Hematologic Malignancies, No. 59 Liuting Street, Ningbo 315010, Zhejiang Province, China. oyguifangoy@163.com

**Received:** August 1, 2022

**Revised:** September 8, 2022

**Accepted:** October 19, 2022

**Published online:** November 16, 2022

**Abstract**

BACKGROUND

The effects of T-cell immunoglobulin mucin molecule-3 (Tim-3), transforming growth factor β (TGF-β), and chemokine-12 (CXCL12) expression on the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) have not been elucidated.

AIM

To examine the correlation between Tim-3, TGF-β and CXCL12 expression and DLBCL prognosis.

METHODS

Lymph node tissues of 97 patients with DLBCL and 93 normal-response hyperplastic lymph node tissues treated from January 2017 to May 2019 were selected as the DLBCL and control groups, respectively. The expression of Tim-3, TGF-β, and CXCL12 was detected immunohistochemically. Patients were followed up for 3 years, and progression-free survival was recorded. Cox multifactorial analysis was performed to analyze the risk factors for poor prognosis.

RESULTS

The positive expression rates of Tim-3, TGF-β, and CXCL12 were higher in DLBCL tissues than in non-cancerous (control) tissues (*P* < 0.05). One-year post-surgery, the positive expression rates of Tim-3, TGF-β, and CXCL12 were higher in patients with effective treatment than in those with ineffective treatment (*P* < 0.05). The 3-year progression-free survival of 97 patients with DLBCL was 67.01% (65/97). Univariate analysis revealed that clinical stage, bone marrow infiltration, International Prognostic Index (IPI) score, Tim-3 positivity, TGF-β positivity, and CXCL12 positivity were associated with poor prognosis (*P* < 0.05). Multivariate Cox regression analysis demonstrated that clinical stage III–IV, bone marrow infiltration, mediate-to-high-risk IPI scores, Tim-3 positivity, TGF-β positivity, and CXCL12 positivity were independent risk factors affecting prognosis (*P* < 0.05).

CONCLUSION

DLBCL tissues exhibit high positive expression of Tim-3, TGF-β, and CXCL12, and a high expression of all three indicates a poor prognosis.

**Key Words:** T-cell immunoglobulin mucin molecule-3; Transforming growth factor β; Chemokine-12; Diffuse large B-cell lymphoma

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Wu H, Sun HC, Ouyang GF. T-cell immunoglobulin mucin molecule-3, transformation growth factor β, and chemokine-12 and the prognostic status of diffuse large B-cell lymphoma. *World J Clin Cases* 2022; 10(32): 11804-11811

**URL:** <https://www.wjgnet.com/2307-8960/full/v10/i32/11804.htm>

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i32.11804

**Core Tip:** Diffuse large B-cell lymphoma (DLBCL) is a malignant tumor with a poor prognosis. T-cell immunoglobulin mucin molecule-3 (Tim-3), transforming growth factor β (TGF-β), and chemokine 12 (CXCL12) can affect the prognosis of solid tumors by participating in the tumor immune escape. Therefore, we analyzed the effects of Tim-3, TGF-β, and CXCL12 expression on DLBCL prognosis. The results suggest that Tim-3 positive, TGF-β positive, and CXCL12 positive are independent risk factors; therefore, they can be used to evaluate the efficacy and prognosis of DLBCL patients.

**INTRODUCTION**

Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogeneous malignancy with a high incidence of recurrent lymphoma, high degree of malignancy, and poor overall prognosis[1]. Reportedly, the five-year overall survival (OS) rate of DLBCL treated with a first-line regimen [*i.e.*, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-based immunotherapy] is 63.12%, whereas an OS of 77.31% has been documented following autologous hematopoietic stem cell transplantation, suggesting that 30%–40% of patients experience unsatisfactory therapeutic effects[2]. Exploring prognostic factors and therapeutic targets is crucial for improving the outcomes of patients with DLBCL. T-cell immunoglobulin and mucin domain 3 (Tim-3)[3], transforming growth factor β (TGF-β)[4], and chemokine 12 (CXCL12)[5] are closely associated with immune function, and can affect the prognosis of various solid tumors by participating in tumor immune escape. Considering the limited number of reports examining the role of Tim-3, TGF-β, and CXCL12 expression in DLBCL prognosis, we analyzed the effects of Tim-3, TGF-β, and CXCL12 expression on the prognosis of 97 patients with DLBCL admitted to our hospital from January 2017 to May 2019.

**MATERIALS AND METHODS**

***General information***

The DLBCL group included 97 patients with DLBCL admitted to our hospital from January 2017 to May 2019, based on the following inclusion criteria: (1) initial diagnosis of DLBCL according to the *Chinese Guidelines for Diagnosis and Treatment of Diffuse Large B Cell Lymphoma* (2013 edition)[6]; (2) age > 18 years; (3) no previous preoperative chemoradiotherapy; (4) postoperative R-CHOP chemotherapy with ≥ 6 courses; (5) estimated survival time > 3 month; and (6) informed consent was obtained from all patients. The exclusion criteria were as follows: (1) conversion from follicular lymphoma; (2) active hepatitis B, human immunodeficiency virus, severe liver and kidney dysfunction, and severe infection; (3) cognitive or mental disorders; (4) allergy to current chemotherapeutic agents; and (5) inability to be followed up or incomplete clinical data. In addition, 93 patients with normal reactive hyperplastic lymph nodes were included in the control group. The DLBCL group comprised 53 males and 44 females, ranging between 18 and 76 years of age (54.36 ± 12.63 years); this group included 48 patients with bone marrow infiltration and 49 without bone marrow infiltration; 41 with clinical stage I–II and 56 with stage III–IV; 54 patients with an Eastern Cooperative Oncology Group score of 0–1 points[7] and 43 with ≥ 2 points; 64 patients with low-risk International Prognostic Index (IPI) scores[8] and 33 with high-risk IPI scores; 50 patients presenting B symptoms (presence of systemic symptoms such as fever, night sweats, and weight loss), and 47 with no B symptoms. The control group consisted of 48 males and 45 females, ranging from 20–83 years of age (56.92 ± 11.08). There were no significant differences in sex and age between the two groups (*P* > 0.05).

***Immunohistochemical examination of Tim-3, TGF-β, and CXCL12 expression in lymphoid tissues***

Surgically excised tissues were subjected to paraffin embedding, baking, deparaffinization, antigen repair, hydrogen peroxide treatment, and serum closure. Primary antibodies against Tim-3, TGF-β, and CXCL12 were added at concentration ratios of 1:200, 1:100, 1:80, respectively (all purchased from Abcam), incubated overnight at 4 °C, and washed with phosphate-buffered saline. Subsequently, the secondary antibody was added for 30 min, followed by diaminobenzidine staining, hematoxylin staining, dehydration, and transparent sealing. Five high-magnification images were randomly selected using a light microscope. Tim-3, TGF-β, and CXCL12 were localized to the cell membrane and scored as a positive cell ratio (positive cell ratio < 1%, 0 points; 1 point, 1%–24%; 2 points, 25%–49%; > 50%, 3 points) and staining intensity score product to achieve a total score (total score ≥ 4 points was deemed positive)[9].

***Follow-up and evaluation***

An outpatient review and telephone follow-up were conducted to record the efficacy 1 year after surgery. The review was according to the criteria in *Chinese Guidelines for Diagnosis and Treatment of Diffuse Large B Cell Lymphoma* (2013 edition)[6]: Complete remission, complete disappearance of lesions; partial remission, lesion narrowing of ≥ 50% and no appearance of new lesions; stable disease, lesion size reduction of < 50%; progression or recurrence, lesion size increases by 50% or new lesions appear. Complete remission and partial remission are considered effective, whereas stable disease, progression, or recurrence are considered ineffective. The number of patients with no disease progression, recurrence, or death within three years (calculated from the date of diagnosis) was determined.

***Statistical analysis***

Data analysis was performed using the SPSS 22.0 software (IBM Corp., Armonk, NY, USA). Normal distribution data were presented as mean ± SD using the independent sample *t*-test and count data as percentages (%). The *χ*2 test was performed to compare groups. Statistical significance was set at *P* < 0.05.

**RESULTS**

***Comparison of Tim-3, TGF-β, and CXCL12 expression between cancerous and adjacent tissues***

DLBCL tissues exhibited higher expression rates of Tim-3, TGF-β, and CXCL12 than non-cancerous (control) tissues (*P* < 0.05) (Table 1).

***Comparison of Tim-3, TGF-β, and CXCL12 expression in patients with effective and ineffective DLBCL therapy***

The expression rates of Tim-3, TGF-β, and CXCL12 were higher in patients with effectively treated DLBCL than in those with ineffective treatment (*P* < 0.05), as shown in Table 2.

***Univariate Cox analysis of factors affecting patient outcomes***

After a 3-year follow-up, 65 of 97 patients with DLBCL exhibited progression-free survival (67.01%), and univariate analysis revealed that clinical stage, bone marrow infiltration, IPI score, and Tim-3, TGF-β, and CXCL12 positivity were associated with poor prognosis (*P* < 0.05), as shown in Table 3.

***Multivariate Cox regression analysis of factors affecting patient outcomes***

We performed multivariate regression analysis by including statistically significant indicators from the univariate analysis, revealing that clinical stage III–IV, bone marrow infiltration, moderate-to-high risk in IPI score, Tim-3 positivity, TGF-β positivity, and CXCL12 positivity were independent risk factors associated with prognostic survival (*P* < 0.05), as shown in Table 4.

**DISCUSSION**

DLBCL is a common malignant lymphoma with a poorly understood pathogenesis. Despite continuous progress in clinical diagnosis and available treatments, more than 50% of adult patients still experience early recurrence, progression, and death during the early stage[10]. Although the addition of rituximab to traditional chemotherapy has significantly improved the survival of patients with DLBCL, 30%-40% of patients experience relapse and/or refractory disease and have a poor prognosis. Based on clinical observations, DLBCL exhibits marked heterogeneity, distinct clinical manifestations, chemoradiotherapy responses, prognosis, survival, and other characteristics. Evaluating relevant factors that impact DLBCL prognosis is critical to enabling timely adjustment of treatment options and provide new therapeutic targets. Bone marrow infiltration, IPI score, and Ann Arbor stage were independent prognostic factors. The detection of B cell subtypes, Ki-67 index, and β2-MG had a certain predictive effect on prognosis. Autologous hematopoietic stem cell transplantation is the best treatment for patients with DLBCL. Chemotherapy combined with rituximab can enhance efficacy[11].

Immune deficiency is closely associated with poor prognosis of DLBCL. Tim-3, TGF-β, and CXCL12 are related to the immune function of malignant tumors; however, reports on DLBCL are inconsistent[12]. Tim-3 is a transmembrane protein located on chromosome 5 at position 33.2. This immune molecule can be expressed in various immune cells and non-Hodgkin’s lymphoma tissue endothelial cells. Tim-3 mainly inhibits the proliferation and activation of Th1 cells and macrophages and promotes tumor immune escape by binding to its ligand, galectin-9[13]. Reduced Tim-3 expression can enhance the killing function of lymphocytes in DLBCL cells (SUDHL-10), suggesting that Tim-3 has an immunosuppressive function[14]. TGF-β is an immunosuppressor secreted by tumor cells that regulates self-growth, differentiation, and immune function. TGF-β has been shown to inhibit normal T-cell immune-killing function while maintaining regulatory T-cell function to avoid severe autoimmune disease. In animal experiments, DLBCL mice exhibit immunosuppression and dysregulated regulatory T-cell ratios, thus facilitating tumor cell evasion of immune system surveillance and promoting tumorigenesis and progression. CXCL12 is a chemokine secreted by osteoclasts, endothelial cells, and epithelial cells of the central nervous system, and is a pro-inflammatory mediator secreted by cancer-related fibroblasts. CXCL12 regulates neoangiogenesis, tumor cell proliferation, and migration of various solid tumors by binding to chemokine 4 (CXCL4)[15]. Blocking the CXCL12/CXCL4 pathway can enhance tumor T-cell infiltration, reduce regulatory T-cell production, and enhance antitumor activity[16]. CXCL12 expression was markedly heterogeneous in different tumors, indicating the importance of exploring CXCL12 expression in DLBCL.

In this study, we found that Tim-3, TGF-β, and CXCL12 expressions were upregulated in DLBCL tissues. Moreover, patients with DLBCL who were effectively treated exhibited higher expression rates of Tim-3, TGF-β, and CXCL12 than those with ineffective treatment. These findings suggest that Tim-3, TGF-β, and CXCL12 participate in DLBCL occurrence, and the effect of DLBCL chemotherapy can be evaluated to a certain extent. Furthermore, the Tim-3-positive expression rate of tumor-infiltrating T cells was 76.2% in patients with DLBCL. In addition, the progression-free survival of Tim-3-positive patients was lower than that of Tim-3-negative patients[17]; these findings are consistent with those observed in the present study. With the continuous progress in R-CHOP chemotherapy, TGF-β expression gradually decreases, indicating that TGF-β is related to DLBCL progression[18]. However, few studies have examined the progression and prognosis of DLBCL in association with CXCL12, and current studies have mainly involved *in vitro* experiments. Ibrutinib can target the CXCL12/CXCL4 chemotaxis axis and inhibit colony formation of stromal cells in the human spinal cord, thus improving drug-resistant DLBCL[19]. Reduced expression of CXCL12/CXCL4 was found to inhibit the growth of DLBCL cell lines in a dose-dependent manner, indicating its potential involvement in the occurrence and progression of DLBCL[20]. In this study, multivariate Cox regression analysis revealed that clinical stage, bone marrow infiltration, IPI score, Tim-3 positivity, TGF-β positivity, and CXCL12 positivity were independent risk factors related to prognostic survival, and clinical stage, bone marrow infiltration, and IPI score were common indicators of poor prognosis that are widely employed in clinical settings. The prognostic impact of Tim-3, TGF-β, and CXCL12 positivity suggested that all three could be effective predictors of prognosis and could be developed as novel clinical therapeutic targets. With the application of clinical anti-CD20 monoclonal antibody drugs, the prognosis of patients with DLBCL has considerably improved. Traditional chemotherapeutic drugs are prone to drug resistance, myelosuppression, and serious infection complications, and immunotherapy has gradually gained momentum as a treatment strategy for DLBCL. CXCL12/CXCL4 can reportedly be blocked, and chemotaxis axis can further disrupt the interaction of PD-1/PD-L1 and improve T-cell infiltration and antitumor activity[21]. Accordingly, combination therapy with a CXCL4 blocker and an immune checkpoint inhibitor may provide a new direction for treating malignancies. Therefore, regulating immune cells through the immunosuppressive factors Tim-3, TGF-β, and CXCL12 may be a clinically valuable strategy for improving the prognosis of DLBCL.

Furthermore, these findings would provide a great reference for observing and predicting the prognosis of DLBCL. However, there are still some limitations to this study: (1) the sample size was small and the sample source was single-center, so it is necessary to further expand the sample size for multicenter studies; and (2) longer follow-up time cannot completely avoid data loss and measurement deviation.

**CONCLUSION**

In conclusion, Tim-3, TGF-β, and CXCL12 exhibit a high positive expression rate in DLBCL and can be used to evaluate the efficacy and prognosis of R-CHOP chemotherapy. Moreover, these factors could be potential prognostic indicators of DLBCL.

**ARTICLE HIGHLIGHTS**

***Research background***

Diffuse large B-cell lymphoma (DLBCL) is a malignant tumor with biological heterogeneity characterized by high recurrence, high malignancy, and poor overall prognosis. Exploring the prognostic factors and therapeutic targets of DLBCL is crucial to improve patient prognosis. T-cell immunoglobulin and mucin domain 3 (Tim-3), transforming growth factor β (TGF-β), and chemokine 12 (CXCL12) are closely related to immune function and can affect the prognosis of various solid tumors by participating in tumor immune escape.

***Research motivation***

Owing to limited reports on the role of Tim-3, TGF-β, and CXCL12 expression in the prognosis of DLBCL, their effects on the prognosis of DLBCL patients remain unclear.

***Research objectives***

We investigated the relationship between Tim-3, TGF-β, and CXCL12 expression and DLBCL prognosis.

***Research methods***

The lymph node tissues of 97 patients with DLBCL and 93 patients with normal reactive hyperplasia were selected as DLBCL and control groups, respectively. The expression of Tim-3, TGF-β, and CXCL12 was detected using immunohistochemistry. The patients were followed up for 3 years, and progression-free survival was recorded. Cox multivariate analysis was used to analyze the risk factors for poor prognosis.

***Research results***

Clinical stage III–IV, bone marrow infiltration, high-risk IPI score, Tim-3 positivity, TGF-β positivity, and CXCL12 positivity were independent risk factors affecting the prognosis of DLBCL.

***Research conclusions***

Tim-3, TGF-β, and CXCL12 have high positive expression rates in DLBCL and can be used to evaluate the efficacy and prognosis of R-CHOP chemotherapy. In addition, these factors may serve as potential prognostic biomarkers for DLBCL.

***Research perspectives***

Future work and clinical research can further validate the accuracy of the experimental results by expanding the sample size and conducting multicenter studies, and ultimately applying the results to the prognostic analysis of DLBCL.

**REFERENCES**

1 **Thandra KC**, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-Hodgkin's Lymphoma. *Med Sci (Basel)* 2021; **9** [PMID: 33573146 DOI: 10.3390/medsci9010005]

2 **Liu Y**, Ma PP, Feng H, Luo MN, Li XY, Lei D, Liu HP, Niu F, Wang XN, He PC. [Clinical analysis of RCHOP regimen combined with involved-field radiotherapy for patients with diffuse large B-cell lymphoma]. *Guoji Shuxue Ji Xueyexue Zazhi* 2021; **44**: 54-62 [DOI: 10.3760/cma.j.cn511693-20200612-00126]

3 **Zhang T**, Ren T, Song Z, Zhao J, Jiao L, Zhang Z, He J, Liu X, Qiu L, Li L, Zhou S, Meng B, Zhai Q, Ren X, Qian Z, Wang X, Zhang H. Corrigendum to "Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma". *J Immunol Res* 2021; **2021**: 4972043 [PMID: 33628842 DOI: 10.1155/2021/4972043]

4 **Yi LY**, Wang JY, Tao QS, WanYan ZX, Zhu FF, Wang HP, Wang ZT, Zhai ZM. Effect of cellular senescence-induced accumulation of inhibitory cytokines on DLBCL cell function. *Auhui Yike Daxue Xuebao* 2021; **56**: 1350-1355 [DOI: 10.19405/j.cnki.issn1000-1492.2021.09.002]

5 **Du H**, Gao L, Luan J, Zhang H, Xiao T. C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges. *Acta Haematol* 2019; **142**: 64-70 [PMID: 31096215 DOI: 10.1159/000497430]

6 **Chinese Society of Hematology, Chinese Medical Association**; Chinese Society of Lymphoma, Chinese Anti-cancer Association. [Chinese guidelines for diagnosis and treatment of diffuse large B cell lymphoma(2013)]. *Zhonghua Xue Ye Xue Za Zhi* 2013; **34**: 816-819 [PMID: 24103886 DOI: 10.3760/cma.j.issn.0253-2727.2013.09.019]

7 **Gayaf M**, Anar C, Canbaz M, Doğan Bİ, Erbaycu AE, Güldaval F. Can LENT Prognostic score (LDH, ECOG performance score, blood neutrophil/lymphocyte ratio, tumor type) change the clinical approach in malignant pleural effusion? *Tuberk Toraks* 2021; **69**: 133-143 [PMID: 34256503 DOI: 10.5578/tt.20219802]

8 **Liu Y**, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. *Am J Hematol* 2019; **94**: 604-616 [PMID: 30859597 DOI: 10.1002/ajh.25460]

9 **Zhou Y**, He S. [Identify the Molecular Target of Diffuse Large B Cell Lymphoma by Bioinformatics Analysis]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* 2020; **28**: 1585-1591 [PMID: 33067958]

10 **Liu XY**, Yuan XL, Ma RJ, Xu H, Yang SW, Nie L, Zhang L, Hu AX, Li Z, Zhu ZM. [Expression of PD-1, TIM-3, LAG-3 and BTLA in diffuse large B-cell lymphoma and its effect on prognosis]. *Zhonghua Yi Xue Za Zhi* 2020; **100**: 2846-2853 [PMID: 32988145 DOI: 10.3760/cma.j.cn112137-20200107-00045]

11 **Liao JH**, Wang XY, Wei XH, Wang MJ. [Prognosis and Its Influencing Factors in Patients with Diffuse Large B-cell Lymphoma]. *Shiyong Aizheng Zazhi* 2020; **35**:1386-1389 [DOI: 10.3969/j.issn.1001-5930.2020.08.043]

12 **Zhong W**, Liu X, Zhu Z, Li Q, Li K. High levels of Tim-3+Foxp3+Treg cells in the tumor microenvironment is a prognostic indicator of poor survival of diffuse large B cell lymphoma patients. *Int Immunopharmacol* 2021; **96**: 107662 [PMID: 33864956 DOI: 10.1016/j.intimp.2021.107662]

13 **Pollari M**, Pellinen T, Karjalainen-Lindsberg ML, Kellokumpu-Lehtinen PL, Leivonen SK, Leppä S. Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma. *Eur J Haematol* 2020; **105**: 712-721 [PMID: 32632935 DOI: 10.1111/ejh.13484]

14 **Ding YW**, Wang PY, Jiao WJ, Shao JG, Ma M. [Analysis of bone marrow invasion morphology and immunophenotype characteristics of diffuse large B cell lymphoma]. *Tianjin Yiyao* 2020; **48**: 204-208, 241 [DOI: 10.11958/20192590]

15 **Shokrgozar N**, Dehghani M, Golmoghaddam H, Moghadam M, Rezaei N, Moayed V, Arandi N. The prognostic significance of immune checkpoint receptor expression in patients with lymphoma: Association with disease status and clinical outcomes. *Asia Pac J Clin Oncol* 2022; **18**: e388-e397 [PMID: 35098660 DOI: 10.1111/ajco.13730]

16 **Weng J**, Chen L, Liu H, Yang XP, Huang L. Ferroptosis Markers Predict the Survival, Immune Infiltration, and Ibrutinib Resistance of Diffuse Large B cell Lymphoma. *Inflammation* 2022; **45**: 1146-1161 [PMID: 35064379 DOI: 10.1007/s10753-021-01609-6]

17 **Min M**, Lin L, Bi CF, Liu WP. [Primary diffuse large B cell lymphoma of the central nervous system: A study of 80 cases of in clinicopathology, immunophenotype and Epstein Barr virus infection]. *Xiandai Zhongliu Yixue* 2021; **29**: 1739-1746 [DOI: 10.3969/j.issn.1672-4992.2021.10.020]

18 **Apollonio B**, Ioannou N, Papazoglou D, Ramsay AG. Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. *Front Oncol* 2021; **11**: 626818 [PMID: 33842331 DOI: 10.3389/fonc.2021.626818]

19 **Shah NN**, Ahn KW, Litovich C, He Y, Sauter C, Fenske TS, Hamadani M. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? *Blood* 2021; **137**: 1416-1423 [PMID: 33120429 DOI: 10.1182/blood.2020007939]

20 **Zhao ZQ**, Zheng CC, Wang LS, Han WE, Su LP. [Analysis of prognostic affecting factors in 355 patients with diffuse large B-cell lymphoma]. *Zhongliu Yanjiu Yu Linchuang* 2020; **32**: 849-853 [DOI: 10.3760/cma.j.cn115355-20200325-00143]

21 **Cheson BD**, Nowakowski G, Salles G. Diffuse large B-cell lymphoma: new targets and novel therapies. *Blood Cancer J* 2021; **11**: 68 [PMID: 33820908 DOI: 10.1038/s41408-021-00456-w]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by Ningbo First Hospital.

**Informed consent statement:** All study participants or their legal guardians provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors declare no conflicts of interest related to this study.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE statement checklist of items, and the manuscript was prepared and revised according to the STROBE statement checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 1, 2022

**First decision:** August 21, 2022

**Article in press:** October 19, 2022

**Specialty type:** Hematology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Gupta A, India; Tsukasaki M, Japan **S-Editor:** Wang JL **L-Editor:** A **P-Editor:** Wang JL

**Table 1 Comparison of T-cell immunoglobulin mucin molecule-3, transforming growth factor β, and chemokine 12 expression between cancerous and adjacent tissues, *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Groups** | **Tim-3 positive** |  **TGF-β positive** |  **CXCL12 positive** |
| DLBCL group (*n* = 97) | 73 (75.26) | 51 (52.58) | 82 (84.54) |
| Control group (*n* = 93) | 36 (38.71) | 23 (24.73) | 27 (29.03) |
| *χ*2 value | 25.931 | 15.483 | 59.806 |
| *P* value | 0.000 | 0.000 | 0.000 |

DLBCL: Diffuse large B-cell lymphoma; Tim-3: T-cell immunoglobulin mucin molecule-3; TGF-β: Transforming growth factor β; CXCL12: Chemokine 12.

**Table 2 Comparison of T-cell immunoglobulin mucin molecule-3, transforming growth factor β, and chemokine 12 expression between patients with effective and ineffective after diffuse large B-cell lymphoma treatment, *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Groups** |  **Tim-3 positive** |  **TGF-β positive** |  **CXCL12 positive** |
| Effective (*n* = 51) | 47 (92.16) | 39 (76.47) | 48 (94.12) |
| Ineffective (*n* = 46) | 26 (56.52) | 12 (26.09) | 34 (73.91) |
| *χ*2 value | 16.4939 | 24.6236 | 7.553 |
| *P* value | 0.000 | 0.000 | 0.006 |

Tim-3: T-cell immunoglobulin mucin molecule-3; TGF-β: Transforming growth factor β; CXCL12: Chemokine 12.

**Table 3 Univariate analysis of factors affecting patient outcomes, *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Factors** | ***n*** | **Three-year progression-free survival** | ***χ*2 value** | ***P* value** |
| Sex | Male | 53 | 40 (75.47) | 3.784 | 0.052 |
|  | female | 44 | 25 (56.82) |  |  |
| Age (yr) | ≥ 50 | 54 | 37 (68.52) | 0.125 | 0.723 |
|  | < 50 | 43 | 28 (65.12) |  |  |
| Bone marrow infiltration  | Presence | 48 | 45 (93.75) | 30.733 | 0.000 |
|  | Absence | 49 | 20 (40.82) |  |  |
| B symptom | Presence | 50 | 31 (62.00) | 1.172 | 0.279 |
|  | Absence | 47 | 34 (72.34) |  |  |
| Clinical stages  | I-II stage | 41 | 10 (24.39) | 58.355 | 0.000 |
|  | III-IV stage | 56 | 55 (98.21) |  |  |
| ECOG grade | 0-1 points | 54 | 34 (62.96) | 0.903 | 0.342 |
|  | ≥ 2 points | 43 | 31 (72.09) |  |  |
| IPI grade | Low-risk | 64 | 33 (51.56) | 20.307 | 0.000 |
|  | Medium-high risk | 33 | 32 (96.97) |  |  |
| Tim-3 expression | Positive | 73 | 60 (82.19) | 30.760 | 0.000 |
|  | Negative | 24 | 5 (20.83) |  |  |
| TGF-β expression | Positive | 51 | 49 (96.08) | 41.105 | 0.000 |
|  | Negative | 46 | 16 (34.78) |  |  |
| CXCL12 expression | Positive | 82 | 60 (73.17) | 9.103 | 0.003 |
|  | Negative | 15 | 5 (33.33) |  |  |

ECOG: Eastern Cooperative Oncology Group; IPI: International Prognostic Index; Tim-3: T-cell immunoglobulin mucin molecule-3; TGF-β: Transforming growth factor β; CXCL12: Chemokine 12.

**Table 4 Multivariate Cox analysis affecting patient outcomes**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  **Variables** | ***r*** | **SD** | **Wald** | ***P* value** | **OR** | **95%CI** |
| Bone marrow infiltration | 0.820 | 0.251 | 10.686 | 0.001 | 2.270 | 1.472-3.934 |
| Clinical stages | 1.537 | 0.419 | 13.478 | < 0.001 | 4.649 | 2.940-15.168 |
| IPI score | 0.949 | 0.273 | 12.074 | 0.001 | 2.582 | 1.626-4.741 |
| Tim-3 expression | 1.027 | 0.279 | 13.540 | < 0.001 | 2.792 | 1.744-5.207 |
| TGF-β expression | 1.195 | 0.360 | 11.010 | 0.001 | 3.304 | 1.954-8.019 |
| CXCL12 expression | 1.305 | 0.401 | 10.600 | 0.001 | 3.688 | 2.102-10.117 |

*r*: Regression coefficient; OR: Odds ratio; CI: Confidence interval; IPI: International Prognostic Index; Tim-3: T-cell immunoglobulin mucin molecule-3; TGF-β: Transforming growth factor β; CXCL12: Chemokine 12; DLBCL: Diffuse large B-cell lymphoma.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**